Veteran private-equity and healthcare operator focused on scaling specialty pharma and services businesses across North America and Europe. Alan Rosenfield brings corporate-development and M&A experience, advising boards on commercialization strategy, licensing and carve-outs while overseeing portfolio-company performance and capital allocation. Known for operational rigor, deal execution and post-acquisition integration, frequently active as an investor, board director and interim CRO/CBO in growth-stage healthcare companies.
Veteran private-equity and healthcare operator focused on scaling specialty pharma and services businesses across North America and Europe. Alan Rosenfield brings corporate-development and M&A experience, advising boards on commercialization strategy, licensing and carve-outs while overseeing portfolio-company performance and capital allocation. Known for operational rigor, deal execution and post-acquisition integration, frequently active as an investor, board director and interim CRO/CBO in growth-stage healthcare companies.
Operates a hands-on, value‑creation approach focused on mid-market specialty pharma and healthcare services in North America and Europe. Prioritizes platform investments and buy-and-build roll-ups where operational playbooks, commercialization acceleration, licensing optimization and disciplined capital allocation drive EBITDA expansion. Investment style blends private‑equity control or minority-stewardship with active board roles and interim commercial leadership, targeting scalable revenue growth and margin improvement over a medium-term (3–5 year) hold period.
Operates a hands-on, value‑creation approach focused on mid-market specialty pharma and healthcare services in North America and Europe. Prioritizes platform investments and buy-and-build roll-ups where operational playbooks, commercialization acceleration, licensing optimization and disciplined capital allocation drive EBITDA expansion. Investment style blends private‑equity control or minority-stewardship with active board roles and interim commercial leadership, targeting scalable revenue growth and margin improvement over a medium-term (3–5 year) hold period.
| Trades 1585 | Longs Won 1172/1585 73% | Profit Factor 8.17 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $600,410.29 |
| Average Win $124,960.81 | Best Trade (Aug 28) $18.01M | Sharpe Ratio -9.94 |
| Average Loss -$43,406.35 | Worst Trade (Sep 30) -$3.06M | Z-Score 15.7 (100%) |
| Commissions $0 | Avg. Trade Length 1y 2m 2d | Expectancy $81,089.75 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 8,929 | 8,036 | 7,143 | 6,250 | 5,357 | 4,464 | 3,571 | 2,679 | 1,786 | 893 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 68,795 | $13.44M | $21.25M | - | $7.82M | 58.16% | -7.354% |
ABBV AbbVie Inc. | 22,863 | $4.81M | $5.74M | - | $928,155.24 | 19.3% | -2.513% |
ABT Abbott Laboratories | 13,560 | $1.23M | $1.43M | - | $202,858 | 16.49% | +0.085% |
AFL Aflac Inc. | 5,968 | $492,360.47 | $760,800.64 | - | $268,440.17 | 54.52% | +0.094% |
AGX Argan Inc. | 287 | $229,184 | $163,713.41 | - | -$65,470.59 | -28.57% | -1.628% |
AMAT Applied Materials, Inc. | 4,828 | $900,001.42 | $2.45M | - | $1.55M | 172.34% | +1.176% |
AMGN Amgen Inc. | 6,712 | $2.15M | $2.59M | - | $438,515.1 | 20.43% | -0.64% |
AMT American Tower Corporation | 4,707 | $1.02M | $816,005.52 | - | -$201,744.74 | -19.82% | -0.631% |
AMZN Amazon.com Inc | 54,717 | $8.9M | $14.86M | - | $5.96M | 67.01% | +15.321% |
ANET Arista Networks, Inc. | 21,270 | $2.65M | $3.84M | - | $1.18M | 44.65% | +5.456% |
APH Amphenol Corporation | 3,686 | $228,173.76 | $296,170.1 | - | $67,996.34 | 29.8% | +0.551% |
AVGO Broadcom Inc. | 8,277 | $1.13M | $3.22M | - | $2.09M | 185.05% | +0.371% |
BA Boeing Company | 5,601 | $1.2M | $1.21M | - | $9,368.21 | 0.78% | -2.155% |
BAC Bank of America Corporation | 49,675 | $2.27M | $3.08M | - | $810,850.73 | 35.78% | +0.356% |
BHP BHP Group Ltd. | 7,353 | $451,727.44 | $621,254.97 | - | $169,527.53 | 37.53% | -1.641% |
BIL SPDR Bloomberg 1-3 Month T-Bill ETF | 21,894 | $2.01M | $2.01M | - | $842.71 | 0.04% | +0.033% |
BKR Baker Hughes Company | 8,522 | $292,035.46 | $515,495.78 | - | $223,460.32 | 76.52% | +0.985% |
BLK BlackRock, Inc. | 2,974 | $2.84M | $3.24M | - | $399,086.35 | 14.03% | -0.727% |
BND Vanguard Total Bond Market Index Fund | 12,989 | $953,174.58 | $938,195.47 | - | -$14,979.11 | -1.57% | -0.262% |
BNDX Vanguard Total International Bond ETF | 10,510 | $516,723.32 | $502,062.7 | - | -$14,660.62 | -2.84% | -0.23% |